prostate cancer

New research suggests that analysing the biology of prostate cancer tumours can help doctors identify which patients are most likely to benefit from hormone therapy. The findings could support more personalised treatment decisions, allowing clinicians to target therapy at those most likely to respond rather than applying it universally. The report has drawn attention in medical news coverage.

Doctors are highlighting theranostics, an emerging approach to treating advanced prostate cancer that pairs diagnostic imaging with targeted therapy in a single process. The method allows physicians to detect cancer cells and deliver radiation treatment directly to them, potentially improving outcomes for patients whose disease no longer responds to standard therapies.